Rubius Therapeutics Announces Preclinical Data Supporting its Lead Clinical Oncology Program, RTX-240, to be Presented at the Society for Immunotherapy of Cancer’s Annual Meeting

NEXT STORY
Genmab to Host Capital Markets Day
PREV STORY
OpGen Provides Business and Pipeline Update and Announces Preliminary Unaudited Revenue and Cash Position for the Third Quarter 2020
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

HTG Molecular Diagnostics and Oncologie, Inc. Complete Master Agreement to Partner on Biomarker Development for Immuno-oncology Drug Development

TUCSON, Ariz., Aug. 03, 2018 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) ...

author_avatar
NASDAQ Market News

Kessler Topaz Meltzer & Check, LLP: Securities Fraud Class Action Filed Against Novavax, Inc. with Lead Plaintiff Deadline Approaching

author_avatar
NASDAQ Market News

Progenity Announces Oral Presentation on Treatment of Gastrointestinal Disorders at 34th Belgian Week of Gastroenterology

author_avatar
NASDAQ Market News